Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Med Mal Infect ; 50(1): 43-48, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31088755

ABSTRACT

BACKGROUND: Little data is available on HIV-infected patients aged over 75years. METHODS: A descriptive study of HIV-infected patients aged over 75years was conducted in six hospitals of the Pays de la Loire region, France. Socio-demographic, immuno-virological, and therapeutic characteristics were collected via an electronic medical record software (Nadis®). To assess frailty, a simplified geriatric assessment was conducted during an HIV routine visit. RESULTS: Among the 3965 patients followed in the six centers, 65 (1.6%) were aged over 75years. From January to May 2016, 51 patients were included in the study: median age 78.7years, male patients 74.5%, homosexual transmission 41.2%, living at home 98% and single in 54.5% of cases, median duration of HIV infection 18.8years, median CD4 nadir 181 cells/mm3; CDC stage C 36.4%. All patients were on antiretroviral therapy and 98% of them had an HIV RNA<50c/mL; 82% of patients had at least one comorbidity and 58% at least two comorbidities. Eleven of 51 patients (21.6%) were diagnosed as at risk of frailty and 2/51 (3.9%) were considered frail. Cognitive disorders were diagnosed in 60.8%, depression in 35.3%, malnutrition in 25.5%, and vitamin D deficiency in 45.9%. CONCLUSIONS: HIV-infected patients aged above 75years are well-managed, but the prevalence of geriatric comorbidities is high.


Subject(s)
HIV Infections , Age Factors , Aged , Aged, 80 and over , Cross-Sectional Studies , Epidemiologic Studies , Female , France/epidemiology , Geriatric Assessment , HIV Infections/complications , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Male
2.
AIDS Behav ; 20(2): 339-44, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26271816

ABSTRACT

This cross-sectional study evaluates the prevalence and factors associated with sleep disturbances in French adult HIV-infected outpatients. Patients fullfilled a self-administered questionnaire on their health behavior, sleep attitudes (Pittsburgh sleep quality index, PSQI), quality of life and depression; 1354 patients were enrolled. Median sleeping time was 7 h. Poor sleep quality was observed in 47 % of the patients, and moderate to serious depressive symptoms in 19.7 %. Factors significantly associated with sleep disturbances were depression, male gender, active employment, living single, tobacco-smoking, duration of HIV infection, nevirapine or efavirenz-including regimen. Prevalence of poor sleepers is high in this HIV adult outpatient population. Associated factors seem poorly specific to HIV infection and more related to social and psychological status. Taking care of these disturbances may prove to be an effective health management strategy.


Subject(s)
Depression/epidemiology , HIV Infections/complications , Outpatients/statistics & numerical data , Sleep Initiation and Maintenance Disorders/epidemiology , Sleep Wake Disorders/epidemiology , Sleep , Adult , Anti-HIV Agents/administration & dosage , Cross-Sectional Studies , Depression/complications , Female , France/epidemiology , HIV Infections/drug therapy , Humans , Male , Middle Aged , Prevalence , Quality of Life , Risk Factors , Sleep Initiation and Maintenance Disorders/complications , Sleep Wake Disorders/diagnosis , Surveys and Questionnaires , Young Adult
3.
Pathol Biol (Paris) ; 47(5): 563-5, 1999 May.
Article in French | MEDLINE | ID: mdl-10418041

ABSTRACT

Due to its long half-life (25-30 hours) the once daily administration of nevirapine would appear logical but we do not have data regarding the tolerability and efficacy of this schedule. We have therefore tried to evaluate this schedule in 93 HIV-infected patients beginning a treatment containing nevirapine. The tolerability of once daily nevirapine was similar to the usual schedule with 15% of mucocutaneous allergy. The immunologic and virologic efficacy of once daily nevirapine was confirmed with a mean RNA HIV decrease of 1.4 log, 1.3 log, 1.1 log and 1.3 log at M1, M3, M6 and M9 respectively. The best results were observed in naïve patients. Residual plasma concentration of nevirapine was performed in 35 patients with a mean value of 3.8 mg/l.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Nevirapine/therapeutic use , Adult , Aged , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/adverse effects , CD4 Lymphocyte Count , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Nevirapine/administration & dosage , Nevirapine/adverse effects , RNA, Viral/blood , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...